Home / Health / Novo Nordisk: Oral GLP-1s to dominate market
Novo Nordisk: Oral GLP-1s to dominate market
13 Jan
Summary
- Oral GLP-1 drugs may capture over a third of the market by 2030.
- Novo Nordisk executive sees pills expanding treatment to new patient groups.
- Updated market views reflect better understanding of patient behavior.
By 2030, oral GLP-1 weight-loss drugs are anticipated to represent more than a third of the total GLP-1 market, a significant increase from earlier projections, a Novo Nordisk executive stated. This updated perspective, shared on Monday, stems from a deeper comprehension of patient behavior in an evolving, consumer-focused obesity market where self-pay is common.
The executive highlighted that Novo Nordisk's newly released oral Wegovy is expected to broaden treatment accessibility to underrepresented demographics, such as men and younger patients. The convenience of an oral option is seen as a key factor in reaching individuals who might not fully acknowledge obesity as a disease or are reluctant to use injectables.
This market reassessment by Novo Nordisk comes as industry analysts also consider the future impact of oral GLP-1s. Previous forecasts suggested that GLP-1 pills would hold a mid-teen percentage share of the global obesity drug market, estimated to reach $150 billion by 2030.
